Conferences

ecancer travels so that you don't have to. Expore the latest conference coverage in global oncology and find out where we are going next.
Bookmark and Share

SABCS 2017

5 - 9 Dec 2017
Henry B. Gonzales Convention Center, San Antonio, United States of America
SABCS 2017: The latest in CDK inhibition in breast cancer
Prof Nadia Harbeck, Dr Mark Beresford, Dr Shom Goel and Dr Sara Hurvitz
SABCS 2017: The latest in CDK inhibition in breast cancer ( Prof Nadia Harbeck, Dr Mark Beresford, Dr Shom Goel and Dr Sara Hurvitz )
10 Dec 2017
Circulating tumour cells may predict late recurrence in HR-positive breast cance...
Dr Joseph Sparano - Albert Einstein Cancer Center, New York, USA
Circulating tumour cells may predict late recurrence in HR-positive breast cancer patients ( Dr Joseph Sparano - Albert Einstein Cancer Center, New York, USA )
9 Dec 2017
Postmenopausal women who lose weight may have reduced breast cancer risk
Prof Rowan Chlebowski - City of Hope, Duarte, USA
Postmenopausal women who lose weight may have reduced breast cancer risk ( Prof Rowan Chlebowski  - City of Hope, Duarte, USA )
9 Dec 2017
Talazoparib vs physicians choice for patients with mBRCA1 breast cancer
Prof Jennifer Litton - MD Anderson Cancer Center, Houston, USA
Talazoparib vs physicians choice for patients with mBRCA1 breast cancer ( Prof Jennifer Litton - MD Anderson Cancer Center, Houston, USA )
9 Dec 2017
CDK 4/6 inhibitors for older women with HR-positive breast cancer
Harpreet Singh - FDA, USA
CDK 4/6 inhibitors for older women with HR-positive breast cancer ( Harpreet Singh - FDA, USA )
9 Dec 2017
Reducing risk of breast cancer recurrence and death with increased dose density
Prof Richard Gray - University of Oxford, Oxford, UK
Reducing risk of breast cancer recurrence and death with increased dose density ( Prof Richard Gray - University of Oxford, Oxford, UK )
9 Dec 2017
Breast cancer therapy resistance mediated by FGFR amplification
Dr Luigi Formisano - Vanderbilt University Medical Center, Nashville, USA
Breast cancer therapy resistance mediated by FGFR amplification ( Dr Luigi Formisano - Vanderbilt University Medical Center, Nashville, USA )
9 Dec 2017
The significance of CEACAM 5 in metastases of triple negative breast cancer
Emily Powell - MD Anderson Cancer Center, Houston, USA
The significance of CEACAM 5 in metastases of triple negative breast cancer ( Emily Powell - MD Anderson Cancer Center, Houston, USA )
9 Dec 2017
Results of the MONALEESA 7 trial
Prof Debu Tripathy - MD Anderson Cancer Center, Houston, USA
Results of the MONALEESA 7 trial ( Prof Debu Tripathy - MD Anderson Cancer Center, Houston, USA )
9 Dec 2017
The REACT trial: Celecoxib vs placebo for primary breast cancer
Prof Charles Coombes - Imperial College School of Medicine, London, UK
The REACT trial: Celecoxib vs placebo for primary breast cancer ( Prof Charles Coombes - Imperial College School of Medicine, London, UK )
9 Dec 2017
Rationale and recruitment in the PARTNER trial
Dr Jean Abraham - University of Cambridge, Cambridge, UK
Rationale and recruitment in the PARTNER trial ( Dr Jean Abraham - University of Cambridge, Cambridge, UK )
9 Dec 2017
The role of axiliary node dissection in modern breast cancer surgery
Dr Viviana Galimberti - European Institute of Oncology, Milan, Italy
The role of axiliary node dissection in modern breast cancer surgery ( Dr Viviana Galimberti - European Institute of Oncology, Milan, Italy )
9 Dec 2017
Anastrozole duration for post-menopausal breast cancer patients after 5 years of...
Dr Michael Gnant - Medizinischen Universität Wien, Vienna, Austria
Anastrozole duration for post-menopausal breast cancer patients after 5 years of endocrine therapy ( Dr Michael Gnant - Medizinischen Universität Wien, Vienna, Austria )
9 Dec 2017
ER positive breast cancer: Screening for clinical variables to predict late dist...
Dr Ivana Sestak - Queen Mary University of London, London, UK
ER positive breast cancer: Screening for clinical variables to predict late distance disease recurrence ( Dr Ivana Sestak - Queen Mary University of London, London, UK )
9 Dec 2017
Predicting late breast cancer recurrence with screening assays
Prof Jack Cuzick - Wolfson Institute of Prevention Medicine, London, UK
Predicting late breast cancer recurrence with screening assays ( Prof Jack Cuzick - Wolfson Institute of Prevention Medicine, London, UK )
9 Dec 2017
Individualising treatment of axillary nodes in breast cancer
Prof Tari King - Brigham and Women’s Cancer Center, Boston, USA
Individualising treatment of axillary nodes in breast cancer ( Prof Tari King - Brigham and Women’s Cancer Center, Boston, USA )
8 Dec 2017
The SOFT trial: Comparing adjuvant tamoxifen with ovarian function suppression v...
Prof Gini Fleming - University of Chicago, Chicago, USA
The SOFT trial: Comparing adjuvant tamoxifen with ovarian function suppression via exemestane to tamoxifen alone ( Prof Gini Fleming - University of Chicago, Chicago, USA )
8 Dec 2017
CDK 4/6 inhibitors for older women with HR-positive breast cancer
Harpreet Singh - FDA, USA
CDK 4/6 inhibitors for older women with HR-positive breast cancer ( Harpreet Singh - FDA, USA )
8 Dec 2017
Talazoparib vs physicians choice for patients with mBRCA1 breast cancer
Prof Jennifer Litton - MD Anderson Cancer Center, Houston, USA
Talazoparib vs physicians choice for patients with mBRCA1 breast cancer ( Prof Jennifer Litton - MD Anderson Cancer Center, Houston, USA )
8 Dec 2017
How can scalp-cooling reduce chemotherapy induced hair loss?
Richard Paxman - Paxman Coolers Ltd
How can scalp-cooling reduce chemotherapy induced hair loss? ( Richard Paxman - Paxman Coolers Ltd )
8 Dec 2017
Acupuncture significantly reduces joint pain for breast cancer patients
Prof Dawn Hershman - Columbia University Medical Center, New York, NY
Acupuncture significantly reduces joint pain for breast cancer patients ( Prof Dawn Hershman - Columbia University Medical Center, New York, NY )
7 Dec 2017
Phase III trial data supports current standard 12-month adjuvant trastuzumab for...
Prof Heikki Joensuu - University of Helsinki, Helsinki, Finland
Phase III trial data supports current standard 12-month adjuvant trastuzumab for HER2-positive breast cancer ( Prof Heikki Joensuu - University of Helsinki, Helsinki, Finland )
7 Dec 2017
Temporary ovarian suppression with hormone analogue may preserve fertility durin...
Dr Matteo Lambertini - Institut Jules Bordet, Brussels, Belgium
Temporary ovarian suppression with hormone analogue may preserve fertility during breast cancer chemotherapy ( Dr Matteo Lambertini - Institut Jules Bordet, Brussels, Belgium )
7 Dec 2017
Two years of extended anastrozole therapy as effective as five
Prof Michael Gnant - Medizinischen Universität Wien, Vienna, Austria
Two years of extended anastrozole therapy as effective as five ( Prof Michael Gnant - Medizinischen Universität Wien, Vienna, Austria )
7 Dec 2017
Tandem duplicator phenotypes define 50% of triple negative breast cancers
Dr Ed Liu - The Jackson Laboratory, Bar Harbor, USA
Tandem duplicator phenotypes define 50% of triple negative breast cancers ( Dr Ed Liu - The Jackson Laboratory, Bar Harbor, USA )
7 Dec 2017
Updated genomic screening tool for life-time breast cancer risk
Dr Johnathan Lancaster - Chief Medical Officer of Myriad Genetics, Salt Lake Cit...
Updated genomic screening tool for life-time breast cancer risk ( Dr Johnathan Lancaster - Chief Medical Officer of Myriad Genetics, Salt Lake City, USA )
7 Dec 2017
Temporary ovarian suppression with hormone analogue may preserve fertility durin...
Dr Matteo Lambertini - Institut Jules Bordet, Brussels, Belgium
Temporary ovarian suppression with hormone analogue may preserve fertility during breast cancer chemotherapy ( Dr Matteo Lambertini - Institut Jules Bordet, Brussels, Belgium )
7 Dec 2017
Acupuncture significantly reduces joint pain for breast cancer patients
Prof Dawn Hershman - Columbia University Medical Center, New York, NY
Acupuncture significantly reduces joint pain for breast cancer patients ( Prof Dawn Hershman - Columbia University Medical Center, New York, NY )
7 Dec 2017
Immunotherapy shows early promise for patients with trastuzumab-resistant breast...
Dr Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia
Immunotherapy shows early promise for patients with trastuzumab-resistant breast cancer ( Dr Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia )
7 Dec 2017
HR–positive advanced breast cancer: Ribociclib improved PFS for pre and perimeno...
Prof Debu Tripathy - MD Anderson Cancer Center, Houston, USA
HR–positive advanced breast cancer: Ribociclib improved PFS for pre and perimenopausal women ( Prof Debu Tripathy - MD Anderson Cancer Center, Houston, USA )
7 Dec 2017
HER2low invasive breast cancer: Trastuzumab offers no improvement for invasive d...
Dr Louis Fehrenbacher - Kaiser Permanente Vallejo Medical Center, California, US...
HER2low invasive breast cancer: Trastuzumab offers no improvement for invasive disease free survival ( Dr Louis Fehrenbacher - Kaiser Permanente Vallejo Medical Center, California, USA )
7 Dec 2017
Adjuvant trastuzumab did not improve outcomes for patients with HER2-low breast ...
Dr Louis Fehrenbacher - Kaiser Permanente Vallejo Medical Center, California, US...
Adjuvant trastuzumab did not improve outcomes for patients with HER2-low breast cancer ( Dr Louis Fehrenbacher - Kaiser Permanente Vallejo Medical Center, California, USA )
7 Dec 2017
Increasing the dose intensity of chemotherapy may lower the risk of breast cance...
Prof Richard Gray - University of Oxford, Oxford, UK
Increasing the dose intensity of chemotherapy may lower the risk of breast cancer recurrence and death ( Prof Richard Gray - University of Oxford, Oxford, UK )
7 Dec 2017